Cardiovasc Diabetol: Changes in metformin and high-sensitivity cardiac troponin I and T in patients with type 2 diabetes

Background: Although metformin has been used as a first-line pharmacological approach for over 60 years to moderate hyperglycemia and increase insulin sensitivity, its pleiotropic benefits in reducing complications from type 2 diabetes and the general aging process continue to attract Doctors and scientific researchers from a range of disciplines

Background: Although metformin has been used as a first-line pharmacological approach for over 60 years to moderate hyperglycemia and increase insulin sensitivity, its pleiotropic benefits in reducing complications from type 2 diabetes and the general aging process continue to attract Doctors and scientific researchers from a range of disciplines

Methods: This study was a post hoc analysis of a randomized controlled trial (HOME trial) that included 390 patients with advanced type 2 diabetes who were randomized to receive 850 mg of metformin or placebo up to a daily dose while continuing insulin therapy three times

Results: The study enrolled 390 subjects, of whom 196 received metformin and 194 received placebo

Figure 1 Changes in cardiac troponin I (A) and T (B) with 95% confidence intervals (shaded)

Figure 1 Changes in cardiac troponin I (A) and T (B) with 95% confidence intervals (shaded)

Table 1 Troponin I and Troponin T—baseline, short-term (4 months), and long-term (52 ​​months) comparison (paired-samples Wilcoxon test)

Table 1 Troponin I and Troponin T—baseline, short-term (4 months), and long-term (52 ​​months) comparison (paired-samples Wilcoxon test)

Table 2 Random slope/random intercept model for troponin I

Table 2 Random slope/random intercept model for troponin I

Table 3 Random slope/random intercept model for troponin T

Table 3 Random slope/random intercept model for troponin T

Conclusions: In a post hoc analysis of this 4.

Conclusions: In a post hoc analysis of this 4.

Original source: Stultiens JMG, Top WMC, Kimenai DM, et al.
Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post-hoc analysis of a randomized controlled trial .
Cardiovasc Diabetol 2022 Apr 04;21 (1) Metformin and high-sensitivity cardiac troponin I and T trajectories in type 2 diabetes patients: a post -hoc analysis of a randomized controlled trial